The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a nanoparticle vaccine showed potential to protect from a ‘tripledemic’. Elsewhere, could… Read More
Compounds derived from ‘magic mushrooms’ could be a potential treatment for anorexia nervosa, a study says. A small pilot trial from the Centre for Psychedelic Research at Imperial College London indicates that psilocybin – the active ingredient in psychedelic ‘magic mushrooms’ – may have potential as a treatment for… Read More
One or two doses of psilocybin may improve the mental health of cancer patients when accompanied by psychotherapy, a new report suggests. A second new study found that treatment with psilocybin resulted in lasting, positive personality changes in patients with alcohol use disorder. In the… Read More
Phase II interim data for psilocybin analog CYB003 in major depressive disorder (MDD) showed rapid, robust, and clinically significant reduction of depression symptoms. Of the trial participants, 53.3% responded and 20% are in remission (i.e. no longer meeting the clinical definition of depression) after a single… Read More
In the second part of this series of articles focused on plant-based medicines, DDW’s Megan Thomas evaluates the use of psilocybin in drug discovery. The first part explored medical cannabis. What is the regulatory landscape of psilocybin? Psilocybin is a naturally occurring… Read More
Psilocybin, a psychedelic derived from mushrooms, has been proven effective as a therapy for treatment-resistant depression (TRD) in the largest study of its kind. The results of COMPASS Pathways’ Phase IIb trial have been published in The New England Journal of Medicine (NEJM). Read More
